{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:27:12Z","timestamp":1771493232062,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Reckitt Benckiser"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is a paucity of large\u2010scale studies evaluating the clinical benefit of the Gaviscon Double Action (<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>) alginate\u2010antacid formulation for treating gastroesophageal reflux disease (<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>) symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Randomised double\u2010blind placebo\u2010controlled parallel\u2010group study to evaluate efficacy and safety of Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>in reducing heartburn, regurgitation and dyspepsia symptoms in individuals with mild\u2010to\u2010moderate<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants with symptomatic<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>(<jats:italic>n<\/jats:italic>\u00a0=\u00a01107) were randomised to receive Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>or placebo (two tablets four times daily) for seven consecutive days. The primary endpoint compared the change in Reflux Disease Questionnaire (<jats:styled-content style=\"fixed-case\">RDQ<\/jats:styled-content>) score for the<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>(heartburn + regurgitation) dimension between Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>and placebo. Secondary endpoints compared the change in<jats:styled-content style=\"fixed-case\">RDQ<\/jats:styled-content>scores for individual heartburn, regurgitation and dyspepsia dimensions, overall treatment evaluation (<jats:styled-content style=\"fixed-case\">OTE<\/jats:styled-content>) scores and incidence of adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean<jats:styled-content style=\"fixed-case\">RDQ GERD<\/jats:styled-content>scores: 2.51 for Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>and 2.50 for placebo at baseline; 1.25 for Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>and 1.46 for placebo post treatment. Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>was statistically superior to placebo in reducing<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>and dyspepsia<jats:styled-content style=\"fixed-case\">RDQ<\/jats:styled-content>scores [least\u2010squares mean (<jats:styled-content style=\"fixed-case\">LSM<\/jats:styled-content>) difference:<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>\u22120.21,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001; dyspepsia \u22120.18,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0004], despite a substantial placebo response. The Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>group reported more favourable overall treatment responses than the placebo group across all<jats:styled-content style=\"fixed-case\">OTE<\/jats:styled-content>categories (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). Superior relief of<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>symptoms was observed both in those with non\u2010erosive and those with erosive reflux disease (<jats:styled-content style=\"fixed-case\">LSM<\/jats:styled-content>difference \u22120.14 [<jats:italic>P<\/jats:italic>\u00a0=\u00a00.038] and \u22120.29 [<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001] respectively). Incidence of<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s was similar in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gaviscon<jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>tablets provide effective and safe reduction in acid reflux and dyspepsia symptoms in Chinese individuals with mild\u2010to\u2010moderate<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>. ClinicalTrials.gov:<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01869491<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.13334","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T08:55:05Z","timestamp":1438332905000},"page":"845-854","source":"Crossref","is-referenced-by-count":26,"title":["Retracted: Randomised clinical trial: the clinical efficacy and safety of an alginate\u2010antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (<scp>GERD<\/scp>) in China"],"prefix":"10.1111","volume":"42","author":[{"given":"J.","family":"Sun","sequence":"first","affiliation":[{"name":"Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Tongji Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Zhao","sequence":"additional","affiliation":[{"name":"China\u2010Japan Friendship Hospital Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zheng","sequence":"additional","affiliation":[{"name":"Zhejiang Hospital Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ng","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Yuan","sequence":"additional","affiliation":[{"name":"Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(05)80756-0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-90"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03671.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304269"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2011.17.1.14"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.09.007"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2007.00650.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.132"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.003"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00288-5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i5.747"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2011.01276.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00759.x"},{"key":"e_1_2_7_17_1","first-page":"1023","article-title":"The mode of action alginic acid compound in the reduction of gastroesophageal reflux","volume":"20","author":"Malmud LS","year":"1979","journal-title":"J Nucl Med"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00277.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2006.00800.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800411"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-18"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639040903388290"},{"key":"e_1_2_7_23_1","unstructured":"Gaviscon Double Action: Summary of Product Characteristics. Last revised 28\/01\/2011. Available at:https:\/\/www.medicines.org.uk\/emc\/medicine\/20053(accessed 22 January 15)."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04678.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.046"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/apt.12857","article-title":"Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post\u2010prandial oesophageal acid exposure in GERD patients: a double\u2010blind crossover study","volume":"40","author":"Ruigh A","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12640"},{"key":"e_1_2_7_28_1","unstructured":"Study details on the Clinical.gov trial registry website. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01869491(accessed 22 January 15)."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03451.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-8-37"},{"key":"e_1_2_7_33_1","unstructured":"Reckitt Benckiser Healthcare (UK) Ltd. 0900901 study data on file."},{"key":"e_1_2_7_34_1","unstructured":"Reckitt Benckiser Healthcare (UK) Ltd. GA0917 study data on file."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41217.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04315.x"}],"updated-by":[{"DOI":"10.1111\/apt.15018","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T00:00:00Z","timestamp":1539475200000},"record-id":"19333"},{"DOI":"10.1111\/apt.15018","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T00:00:00Z","timestamp":1539475200000}}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13334","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T08:45:36Z","timestamp":1718009136000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/apt.13334"],"URL":"https:\/\/doi.org\/10.1111\/apt.13334","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]}}}